Compare AbbVie Inc (ABBV) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? AbbVie Inc trades at $249.59 (market cap $441.94B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53. The key difference: AbbVie Inc pays a 2.77% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none, and AbbVie Inc is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| ABBV | QCLN | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $68.47 |
52-Week Low | $197.38 | $36.11 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
QCLN trades at $53.31, up 2.42% on the day, with a bullish technical signal driven by moving averages, though oscillators are neutral. The ETF focuses on clean energy, benefiting from long-term growth themes like rising data center power demand and global energy security investments. Recent news highlights sector momentum but notes regulatory and supply chain pressures.
Outlook is cautiously optimistic, supported by structural energy transition trends, but risks include U.S. permit delays, geopolitical tensions affecting Chinese suppliers, and cost inflation. The absence of key valuation ratios limits fundamental assessment, requiring reliance on sector trends and technical levels for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
